Myelosuppression and Serotonin Syndrome Associated with Concurrent Use of Linezolid and Selective Serotonin Reuptake Inhibitors in Bone Marrow Transplant Recipients | Zendy

Ray Hachem | Zendy; Krystal Hicks | Zendy; Auris Huen | Zendy; Issam Raad | Zendy

Open Access

Myelosuppression and Serotonin Syndrome Associated with Concurrent Use of Linezolid and Selective Serotonin Reuptake Inhibitors in Bone Marrow Transplant Recipients

Author(s) -

Ray Hachem,

Krystal Hicks,

Auris Huen,

Issam Raad

Publication year - 2003

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/375689

Subject(s) - medicine , serotonin syndrome , linezolid , serotonin reuptake inhibitor , serotonin , serotonin uptake inhibitors , bone marrow transplant , bone marrow , serotonergic , bone marrow transplantation , vancomycin , fluoxetine , receptor , biology , bacteria , genetics , staphylococcus aureus

We report 2 cases of serotonin syndrome and myelosuppression in bone marrow transplant recipients who received linezolid in combination with a selective serotonin reuptake inhibitor (SSRI). Given the risks to patients in this high-risk group, we recommend that this combination of medications be avoided if alternative antibiotic therapy is possible. If no alternative therapy is possible, prescribers should discontinue SSRI therapy and monitor these patients closely for evidence of serotonin syndrome or the development of hematological toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research